Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4011972 | 0.92 | MMP12 (1.00) | MMP12MMP13 | |
| SCHEMBL4009376 | 0.90 | MMP12 (0.85) | MMP12MMP13 | |
| SCHEMBL4016505 | 0.86 | MMP12 (1.00) | MMP12MMP13 | |
| SCHEMBL4011348 | 0.84 | MMP12 (0.67) | MMP12MMP13 | |
| SCHEMBL4011339 | 0.84 | MMP12 (0.67) | MMP12MMP13 | |
| SCHEMBL4012640 | 0.84 | MMP12 (0.71) | MMP12MMP13 | |
| SCHEMBL31490342 | 0.84 | MMP12 (0.71) | MMP12MMP13 | |
| SCHEMBL4010337 | 0.83 | MMP12 (0.80) | MMP12MMP13 | |
| SCHEMBL4011224 | 0.83 | MMP12 (0.83) | MMP12MMP13 | |
| SCHEMBL31490343 | 0.83 | MMP12 (0.83) | MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025056602-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF IN TREATMENT OF CONDITIONS AND DISEASES RELATED TO ELASTIN DEFICIENCY AND/OR AGING | Elastin Biosciences Ltd. (GB) | 2025-03-20 | — | — | WO | disclosed |
| EP-2074107-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008057254-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057254-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-05-15 | — | — | WO | disclosed |